The UK's new "notifiable trial" route can shave weeks off your timeline, but only if you sequence your jurisdictions like a chess player rather than a tourist.
The needle-shy are the prize now, and four companies showed up to ADA with a pill and a percentage.
ASCO ended a week ago. The filing and the deal structure that deserve a closer look.
Bundibugyo had no vaccine, no treatment, no diagnostic for seventeen years. It took 900 cases to change the math.
Two qualify as first-in-class among 2032's ten biggest oncology bets. So why is big pharma paying nine figures for assets that haven't read out?
The AI trial pilot survived its own architects' departure. For one more month, the docket is where it gets decided.
Daraxonrasib doubles survival in pancreatic cancer, BMS puts numbers behind its CELMoD bet, and the trial count quietly falls again.
Three ASCO readouts, three announcements that claimed more than the data supported — and one question the conference floor has been too busy to ask.
Anthropic paid $400 million for an eight-month-old stealth biotech and opened a wet lab. The argument: one generalist model, trained heavily on biology, can do more for drug discovery than every specialist tool in the stack.
Cell and gene therapy has its first commercial products, its first profitable company, and its first wave of strategic exits. The exits are as informative as the deals.
The EU pharma reform package has a 2028 implementation date. That is not a reason to wait.
For the first time in ASCO's history, China-only data occupies the plenary slot. A hazard ratio of 0.40 in pancreatic cancer. And Lilly moving the obesity ceiling above bariatric surgery. Chicago has a lot to answer for this week.
